The analysts have lined up and placed their bets. The early over/under for the predicted pricing of a year's course of Provenge per patient is approximately $61,700 according to Luke Timmerman's poll of 7 industry analysts - the folks who should know - even though they're guessing like you and me (maybe a bit more knowledgably than you or me).
Price estimates range from $40 K to $75 K with other analysts not included in this calculation even projecting over $100 K pricing. Not too worry though, this isn't too big a decision for Dendreon - they only have to recoup a $783 M deficit generated since 1992. Nothing at stake here if they set the price too high for any 3rd party payers to foot the bill.
Posted by Bruce Lehr April 16th 2010
UPDATE FROM FIERCE BIOTECH - FULL COURSE OF TREATMENT TO COST $93 K.